LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. IBM
9. HOOD
10. ABBV

Go back to LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

Lexicon Pharma (LXRX) Tops Q4 EPS by 29c, Revenues Miss

March 12, 2020 7:03 AM EDT

Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.48), $0.29 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $8.73 million versus the consensus estimate of $10.26 million.

In 2019, we achieved continued growth in our XERMELO (telotristat ethyl) business of nearly 25% year-over-year and made significant strides in advancing... More